Company intelligence
Granza Bio
Reprogramming Immunity for Target-Specific Medicines
Biotechnology Research
8 employees
Founded 2023
1 public signals
About Granza Bio
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
Verified activity
Signals from Granza Bio
1 published signal